semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Women or men with metastatic or locally relapsed breast cancer manageable with systemic therapy 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. 3. Written informed consent prior to enrollment into the program. 4. Patient aged ≥ 18 years 5. Patient agrees to provide archived primary tumor tissue 6. Patient agrees to provide newly collected metastatic lesions tissue samples (archived material up to 6 months is allowed provided both Formalin Fixed Paraffin Embedded (FFPE) block and Frozen Tissue are available and were collected from the same lesion at the same time) 7. Patient agrees to provide blood samples  The patient has received more than 1 line of systemic therapy (any type) in the metastatic setting 2. Patients who have received prior palliative radiotherapy to the only site that is accessible to biopsy 3. Patients with bone-only metastatic disease 4. Patients with brain-only metastatic disease, unless surgical excision is planned (in which case tissue will be collected for purpose) 5. Known presence of severe hematopoietic, renal, and/or hepatic dysfunction (according to the local PI) 6. Platelet count<100 000/mm3, INR>1.5 (international normalized ratio; blood clotting time) , Albumin<30 7. Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin 8. Any anti-VEGF (vascular endothelial growth factor) or anti-VEGFR (vascular endothelial growth factor receptor) treatment administered less than 4 weeks before new biopsy procedure or no appropriate wash-out period for patients on anticoagulation therapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  BREAST CANCER Patient aged over 18 and under 45 Patient without amenorrhea at diagnosis Performance status less than 2 (according to WHO ) Patient diagnosed with histologically proven non-metastatic breast cancer Clinical Stages I, IIA, IIB and IIIA Positive Hormone Receptors (defined by a rate of 10% of labeled cells and immunohistochemistry (IHC) ) or negative Positive or negative HER2 status ( defined a score of 0 or 1 + by IHC , or a 2 + score by IHC and FISH / ISHS / CISH negative) Patients to be treated with neoadjuvant or adjuvant chemotherapy Satisfying hematological, renal and hepatic functions : PNN> 2,109 / L, platelets > 100 . 109 / L, Hb> 10 g / dl , normal bilirubin, AST and ALT <2.5 upper normal value ( VNS) , alkaline phosphatase <2.5 VSN , creatinine clearance > 60 ml / min Obtaining informed consent in writing, signed and dated  Male patient Metastatic cancer Any T4 tumor (skin invasion, deep grip, inflammatory breast cancer) Patient who underwent surgical castration of ovariectomy or hysterectomy or tubal ligation Patients with endometriosis Pregnant or breastfeeding patients Patients with no effective contraception Patients who have had hormone therapy or chemotherapy Patient who have already taken Gn-RH or LH-RH analogues (chemical castration) Patient whose mother was in menopause early without treatment
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Advanced Gastric Cancer Histologically and CT confirmed resectable advanced gastric cancer No prior treatment No metastases  Having allergic reaction Pregnant R0 resection is not achieved by gastrectomy with D2 lymphadenectomy according to Japanese gastric cancer treatment guidelines 2010 (ver. 3)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Tubular Breast Cancer Stage II Tubular Breast Cancer Stage III Mucinous Breast Cancer Stage II Breast Cancer Female NOS Invasive Ductal Breast Cancer HER2 Positive Breast Cancer Inflammatory Breast Cancer Patients will be eligible for study participation only if they comply with the following Written informed consent according to local regulatory requirements prior to beginning specific protocol procedures Complete baseline documentation must be submitted via MedCODES to GBG Forschungs GmbH Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration from the breast lesion alone is not sufficient. Incisional biopsy or axillary clearance is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion Patients must have stage cT1c cT4a-d disease. Patients with HER2 positive or TNBC are eligible irrespective of nodal status (cN0-cN3). Patients with luminal B-like tumors (defined here as ER and/or PgR >1% stained cells, HER2 negative, Ki-67 >20%) only with histologically (sentinel-node biopsy, core or fine-needle biopsy) involved lymph nodes (pN1-3) In patients with multifocal or multicentric breast cancer, the largest lesion should be measured  Patients with ER and/or PR-positive, HER2-negative breast cancer and Ki <= 20% (any luminal A-like subtype) or luminal B-like (Ki67>20%) subtype without nodal involvement Patients with stages cT1a, cT1b, or any M1 Patients with pure lobular invasive breast cancer Prior chemotherapy for any malignancy Prior radiation therapy for breast cancer Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization) during study treatment Inadequate general condition (not fit for dose-dense, dose-intensified anthracycline-taxane-targeted agents-based chemotherapy) Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Ductal Carcinoma in Situ Clinical diagnosis of Ductal carcinoma in situ (DCIS) or invasive breast cancer Candidate for breast conserving surgery or mastectomy  Pregnant women Prior Breast Cancer diagnosis Adverse reaction to Oxytocyn in the past
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasms Histologically confirmed invasive breast cancer with a primary tumor size of greater than (>) 2 cm HER2-positive breast cancer Participants with multifocal tumors (more than one tumor confined to the same quadrant as the primary tumor) are eligible provided all discrete lesions are sampled and centrally confirmed as HER2 positive Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging system Known hormone receptor status of the primary tumor Participant agreement to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Baseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) Effective contraception as defined by protocol  Stage IV (metastatic) breast cancer Participants who have received prior anti-cancer therapy for breast cancer except those participants with a history of breast lobular carcinoma in situ (LCIS) that was surgically managed or ductal carcinoma in situ (DCIS) treated exclusively with mastectomy. In case of prior history of LCIS/DCIS, >5 years must have passed from surgery until diagnosis of current breast cancer Participants with multicentric (multiple tumors involving more than 1 quadrant) or bilateral breast cancer Participants who have undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes Axillary lymph node dissection or positive sentinel lymph node prior to start of neoadjuvant therapy History of concurrent or previously non-breast malignancies except for appropriately treated (1) non-melanoma skin cancer and (2) in situ carcinomas, including cervix, colon, and skin. A participant with previous invasive non-breast cancer is eligible provided he/she has been disease-free >/= 5 years Treatment with any investigational drug within 28 days prior to randomization Current National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) version (v) 4.0 Any significant concurrent medical or surgical conditions or findings that would jeopardize the participant's safety or ability to complete the study Current pregnancy or breastfeeding
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-94.0,  Common Bile Duct Stones Patients with common bile duct stones (CBDS)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Breast Cancer Stage I-III, HER2-neu positive invasive ductal carcinoma 2. Scheduled to receive adjuvant/neo-adjuvant 5-Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel (FEC-D) chemotherapy 3. Scheduled to receive adjuvant Trastuzumab 4. ECOG Performance status 0-2 5. Adequate baseline imaging on transthoracic echocardiography, and baseline cardiac ejection fraction of ≥ 55%. Additionally, breast cancer patients≥45 years of age and scheduled to receive whole breast radiation therapy will receive two cardiac PET scans  Prior anthracycline chemotherapy 2. History of dilated cardiomyopathy, congestive heart failure, or coronary artery disease 3. Life expectancy less than 15 months 4. Pregnant or lactating women 5. Use of beta receptor antagonists, calcium channel antagonists, angiotensin converting enzyme inhibitors, or angiotensin receptor inhibitors at baseline. 6. Previous chest wall/breast or nodal radiation
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Estrogen Receptor-positive Breast Cancer Invasive Ductal Breast Carcinoma Invasive Ductal Breast Carcinoma With Predominant Intraductal Component Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate Mucinous Ductal Breast Carcinoma Papillary Ductal Breast Carcinoma Progesterone Receptor-positive Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Tubular Ductal Breast Carcinoma The patient must consent to be in the study and must have signed an approved consent form conforming with federal and institutional guidelines Patient must be ≥ 50 years Core biopsy demonstrating breast cancer and receptors that are ER or PR positive Core tissue must have HER 2 negative followed by current ASCO/CAP guidelines The patient must have clinical node negative, stage I breast cancer The surgical treatment must be intended to be a lumpectomy The biopsy site must have been demarcated by a clip(s) Gross disease must be unifocal on Mammo/ MRI imaging Patients must have estrogen receptor (ER) and progesterone receptor (PR) analysis performed on core biopsy Patient must be able to tolerate lying in the prone position with arms extended forward  Age < 50 years Hormone unresponsive breast cancer T-2 ( > 3.0 cm), T-3, Stage III, or Stage IV breast cancer N-1, N-2, or N-3 clinical axillary nodes Mastectomy intended Unwilling to undergo anti-endocrine therapy Suspicious microcalcification, densities, or palpable abnormalities ( in the ipsilateral or contralateral breast) unless biopsied and found to be benign Non-epithelial breast malignancies such as sarcoma or lymphoma Paget's disease of the nipple Proven multicentric carcinoma (invasive or DCIS) in more than one quadrant or separated by > 4 centimeters
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Invasive Breast Cancer Patients must be female Patients must be 18 years of age or older Patients with stage I, II, or III breast cancer that is greater or equal to 2 cm on clinical examination Patients that have biopsy proven invasive breast cancer diagnosed by core needle biopsy Patients who are chemotherapy and radiotherapy naïve for the treatment of the current breast cancer Patients that accept to undergo neoadjuvant chemotherapy Patients with bilateral breast cancer are eligible Patients that understand, accept, and have signed the approved written consent form Patients will need to consent to be part of the study  Patients with one or more of the following conditions are ineligible for this study Patients who have had previous surgery, chemotherapy or radiotherapy for the current breast cancer Patients who are pregnant or breast feeding Psychiatric or addictive disorders or conditions or social factors that may preclude the patient from meeting study requirements
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Tubular Breast Cancer Mucinous Breast Cancer Invasive Ductal Breast Cancer Inflammatory Breast Cancer Women aged ≥18years and ≤70 years 2. At least on measurable disease according to the Response Evaluation in Solid Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size ≥2 cm, T2-4 N0-2M0 3. ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR positive is defined as >1% stained cells and HER2-positive is defined as immuno-histochemistry (IHC) 3+ or FISH ratio ≥ 2.0 4. No prior systemic or loco-regional treatment of breast cancer 5. ECOG 0-2 6. Adequate bone marrow function:WBC≥4.0×109/L, Absolute neutrophil count（ANC）≥1.5×109/L, Platelets（PLT）≥100×109/L, Hemoglobin（Hb）≥90g/L;aspartate aminotransferase(AST),Alanine aminotransferase (ALT)≤1.5 upper normal limit （UNL）, creatinine≤1.5 UNL, bilirubin≤1.5UNL 7. No obvious main organs dysfunction  Unwilling or unable to use an acceptable method of contraception in 8 weeks (including 8 weeks) after final dose of test drug 2. Patient is pregnant or breast feeding 3. Inflammatory breast cancer and metastatic breast cancer 4. Any evidence of sense or motor nerve disorders 5. Patients with medical conditions taht indicate intolerant to neoadjuvant therapy, including uncontrolled cardiovascular disease, severe infection 6. Any concurrent malignancy other than breast cancer 7. Know severe hypersensitivity to any drugs in this study
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 26.0-999.0,  Breast Cancer Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer) Age > 25 Ability and willingness to sign informed consent prior to any study procedure Positive indication of disease on mammogram or MRI scan Candidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeon Ability to undergo up to 90 minutes of PEM imaging  Any active or chronic illness that, in the opinion of the investigators, would make the study unsafe or limit compliance with study procedures Past or present history of active substance abuse (drug or alcohol) Inability to tolerate venous access Pregnant females are excluded from this study. All females of child-bearing potential will undergo a serum pregnancy test within 48 hours prior to FBnTP administration
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Tubular Breast Cancer Mucinous Breast Cancer Invasive Ductal Breast Cancer Inflammatory Breast Cancer Women aged ≥18years and ≤70 years; 2. At least on measurable disease according to the Response Evaluation in Solid Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size ≥2 cm, T2-4 N0-3M0; 3. ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER and/or PR positive was defined as >1% stained cells.HER2-positive is defined as immuno-histochemistry (IHC) 3+ or the ratio of HER2 gene signals to chromosome 17 signals >2.0 or HER2 gene copy >6.0. 4. No prior systemic or loco-regional treatment of breast cancer; 5. Adequate bone marrow function:WBC≥4.0×109/L, Absolute neutrophil count（ANC）≥1.5×109/L, Platelets（PLT）≥100×109/L, Hemoglobin（Hb）≥90g/L;aspartate aminotransferase(AST),Alanine aminotransferase (ALT)≤1.5 upper normal limit (UNL), creatinine≤1.5 UNL, bilirubin≤1.5UNL; 6. No obvious main organs dysfunction  Unwilling or unable to use an acceptable method of contraception in 8 weeks (including 8 weeks) after final dose of test drug; 2. Patient is pregnant or breast feeding; 3. Inflammatory breast cancer and metastatic breast cancer; 4. Any evidence of sense or motor nerve disorders; 5. Patients with medical conditions taht indicate intolerant to neoadjuvant therapy, including uncontrolled cardiovascular disease, severe infection; 6. Any concurrent malignancy other than breast cancer; 7. Know severe hypersensitivity to any drugs in this study